National Gene Vector Biorepository

The National Institutes of Health's National Heart, Lung and Blood Institute (NHLBI) has issued a Special Notice for the National Gene Vector Biorepository (NGVB), a critical contract opportunity in biomedical research. The solicitation seeks a contractor to manage a comprehensive gene therapy research support infrastructure. This contract will oversee a complex repository of genetic materials, including over 70 AAV and lentiviral plasmids, cell lines, and vectors. The opportunity is classified under NAICS category 541715 for research and development in physical, engineering, and life sciences. The contract is structured as an Indefinite Delivery/Indefinite Quantity (IDIQ) agreement with a base 12-month period and four additional 12-month option periods.

The primary objective of this contract is to support gene therapy research through four core functions: maintaining a reagent repository, providing GLP specimen archiving, performing specialized testing services, and storing biospecimens under precise conditions. Contractors must maintain CAP and CLIA certifications, develop a public-facing website, establish an External Advisory Board, and create comprehensive databases for sample tracking. Proposals are due by 2:00 PM EST on January 15, 2025, and must address both Core Administrative Tasks (Task Area A) and Core Laboratory Activities (Task Area B). Eligible contractors will need to demonstrate capabilities in handling sensitive genetic materials, comply with federal security and privacy standards, and have expertise in managing approximately 29,000 existing and 4,000 new tissue samples over the contract period. The contract requires detailed technical and cost proposals, with specific formatting and submission guidelines outlined in the solicitation documents.